CX DAILY

CX Daily: Sinovac’s Covid Fortune Fuels Bitter Boardroom Battle

Published: Jul. 24, 2025 9:20 a.m. GMT+8

00:00

00:00/00:00

Listen to this article 1x

TOP STORIES

Sinovac /

In Depth: Sinovac’s Covid fortune fuels bitter boardroom battle

The Covid-19 pandemic turned Chinese vaccine-maker Sinovac Biotech Ltd. into a global household name after its CoronaVac jab became a billion-dollar money spinner and one of the world’s most administered inoculations against the virus. But hidden away behind its success lies a bitter, decade-long power struggle for control of the company.

Register to read this article for free.

Register

Unlock exclusive discounts with a Caixin group subscription — ideal for teams and organizations.

Subscribe to both Caixin Global and The Wall Street Journal — for the price of one.

Share this article

Open WeChat and scan the QR code

GALLERY

: Gallery: Innovation Takes Off at Flying Vehicle Expo

NEWSLETTERS

Get our CX Daily, weekly Must-Read and China Green Bulletin newsletters delivered free to your inbox, bringing you China's top headlines.

We ‘ve added you to our subscriber list.

Manage subscription

PODCAST

Caixin Deep Dive: How China’s Crypto Ban Makes Disposing of Seized Assets a Lot Harder

00:00

00:00/00:00

MOST POPULAR

1: Sinopec and Saudi Aramco Launch $10 Billion Petrochemical Venture in Fujian

2: Cover Story: How the Yuan is Taking Over the Dollar’s Role in Global Trade

3: Chinese Regions Dial Back Car Subsidies as Funds Dry Up

4: Exclusive: Ex-CSRC Chief Yi Huiman Faces Corruption Probe Likely Linked to ICBC

5: Finance Movers and Shakers: Former Securities Watchdog Chief Yi Huiman Under Graft Probe

SPONSORED

OR